CG Oncology, Inc. (CGON) Stock Forecast & Price Target

Compare

225 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CGON Analyst Ratings

Strong Buy

12 Buy

0 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Oncology, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CGON Stock 12 Month Forecast

Average Price Target

$71.70

▲(89.88% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for CG Oncology, Inc. in the last 3 months. The average price target is $71.70 with a high forecast of $90.00 and a low forecast of $55.00. The average price target represents a 89.88% change from the last price of $37.76.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","56":"$56","91":"$91","38.5":"$38.5","73.5":"$73.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":71.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$71.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$55.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,38.5,56,73.5,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.27,46.86461538461539,50.45923076923077,54.05384615384616,57.64846153846154,61.24307692307693,64.83769230769231,68.43230769230769,72.02692307692308,75.62153846153846,79.21615384615384,82.81076923076924,86.40538461538462,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.27,45.45692307692308,47.643846153846155,49.830769230769235,52.017692307692315,54.20461538461539,56.39153846153847,58.57846153846154,60.76538461538462,62.9523076923077,65.13923076923078,67.32615384615386,69.51307692307692,{"y":71.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.27,44.1723076923077,45.074615384615385,45.97692307692308,46.87923076923077,47.78153846153846,48.683846153846154,49.58615384615385,50.488461538461536,51.39076923076923,52.293076923076924,53.19538461538461,54.097692307692306,{"y":55,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":35.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.77,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.68,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.07,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.86,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$90.00

Average Price Target$71.70

Lowest Price Target$55.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andres Y. Maldonado

H.C. Wainwright

$75

Buy

98.62%

Upside

Reiterated

11/14/25

Valuation and risks to achievement of price target. Our 12-month price target of $75 is based on an equally weighted composite of (a) 88.01/share, as a 20x multiple of taxed and diluted FY34 GAAP EPS of $12.20 discounted back to and (b) an NPV of $62.2/ share (discount rate 12.0%, growth rate 3.0%). The assumptions are in line with the expected P/ E multiple and discount rate of a late development-stage biopharmaceutical company. Risks to achieving our price target include the following: 1) Clinical risk.

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

11/06/25

Optimistic Growth Potential for CG Oncology, Inc. Driven by Positive Regulatory Precedents and Strategic Pricing

Kelsey Goodwin

Piper Sandler

$55

Buy

45.66%

Upside

Reiterated

10/28/25

Piper Sandler Keeps Their Buy Rating on CG Oncology, Inc. (CGON)

Brian Cheng

J.P. Morgan

―

Buy

―

Reiterated

10/20/25

Positive Outlook for CG Oncology: Buy Rating Affirmed Amid Regulatory Progress and Operational Efficiency

Soumit Roy

JonesTrading

$75

Buy

98.62%

Upside

Reiterated

10/16/25

Promising Developments and Market Expansion Potential Drive Buy Rating for CG Oncology, Inc.

Bradley Canino

Guggenheim

$90

Buy

138.35%

Upside

Initiated

10/07/25

CG Oncology initiated with a Buy at GuggenheimCG Oncology initiated with a Buy at Guggenheim

Corinne Johnson

Goldman Sachs

$40→$56

Buy

48.31%

Upside

Reiterated

09/22/25

Goldman Sachs Remains a Buy on CG Oncology, Inc. (CGON)

Sam Slutsky

LifeSci Capital

$90

Buy

138.35%

Upside

Reiterated

09/20/25

CG Oncology, Inc. (CGON) Gets a Buy from LifeSci Capitalwe are adjusting our revenue build for cretostimogene and increasing our price target to $90/share from $82/share

Sean Laaman

Morgan Stanley

$56→$79

Buy

109.22%

Upside

Reiterated

09/17/25

CG Oncology price target raised to $79 from $56 at Morgan StanleyCG Oncology price target raised to $79 from $56 at Morgan Stanley

Alec Stranahan

Bank of America Securities

$62

Buy

64.19%

Upside

Reiterated

09/10/25

Analysts Offer Insights on NA Companies: Reddit Inc Class A (NYSE: RDDT), Solventum Corporation (NYSE: SOLV) and CG Oncology, Inc. (NASDAQ: CGON)

Joshua Schimmer

Cantor Fitzgerald

$75

Buy

98.62%

Upside

Reiterated

09/07/25

Cantor Fitzgerald Keeps Their Buy Rating on CG Oncology, Inc. (CGON)

David Dai

UBS

$60

Buy

58.90%

Upside

Reiterated

08/18/25

Leonid Timashev

RBC Capital

$53

Buy

40.36%

Upside

Reiterated

08/08/25

Wall Street Analysts Are Bullish on Top NA Picks

George Farmer

Scotiabank

$23

Hold

-39.09%

Downside

Reiterated

05/14/25

Scotiabank Reaffirms Their Hold Rating on CG Oncology, Inc. (CGON)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andres Y. Maldonado

H.C. Wainwright

$75

Buy

98.62%

Upside

Reiterated

11/14/25

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

11/06/25

Optimistic Growth Potential for CG Oncology, Inc. Driven by Positive Regulatory Precedents and Strategic Pricing

Kelsey Goodwin

Piper Sandler

$55

Buy

45.66%

Upside

Reiterated

10/28/25

Piper Sandler Keeps Their Buy Rating on CG Oncology, Inc. (CGON)

Brian Cheng

J.P. Morgan

―

Buy

―

Reiterated

10/20/25

Positive Outlook for CG Oncology: Buy Rating Affirmed Amid Regulatory Progress and Operational Efficiency

Soumit Roy

JonesTrading

$75

Buy

98.62%

Upside

Reiterated

10/16/25

Promising Developments and Market Expansion Potential Drive Buy Rating for CG Oncology, Inc.

Bradley Canino

Guggenheim

$90

Buy

138.35%

Upside

Initiated

10/07/25

CG Oncology initiated with a Buy at GuggenheimCG Oncology initiated with a Buy at Guggenheim

Corinne Johnson

Goldman Sachs

$40→$56

Buy

48.31%

Upside

Reiterated

09/22/25

Goldman Sachs Remains a Buy on CG Oncology, Inc. (CGON)

Sam Slutsky

LifeSci Capital

$90

Buy

138.35%

Upside

Reiterated

09/20/25

CG Oncology, Inc. (CGON) Gets a Buy from LifeSci Capitalwe are adjusting our revenue build for cretostimogene and increasing our price target to $90/share from $82/share

Sean Laaman

Morgan Stanley

$56→$79

Buy

109.22%

Upside

Reiterated

09/17/25

CG Oncology price target raised to $79 from $56 at Morgan StanleyCG Oncology price target raised to $79 from $56 at Morgan Stanley

Alec Stranahan

Bank of America Securities

$62

Buy

64.19%

Upside

Reiterated

09/10/25

Analysts Offer Insights on NA Companies: Reddit Inc Class A (NYSE: RDDT), Solventum Corporation (NYSE: SOLV) and CG Oncology, Inc. (NASDAQ: CGON)

Joshua Schimmer

Cantor Fitzgerald

$75

Buy

98.62%

Upside

Reiterated

09/07/25

Cantor Fitzgerald Keeps Their Buy Rating on CG Oncology, Inc. (CGON)

David Dai

UBS

$60

Buy

58.90%

Upside

Reiterated

08/18/25

Leonid Timashev

RBC Capital

$53

Buy

40.36%

Upside

Reiterated

08/08/25

Wall Street Analysts Are Bullish on Top NA Picks

George Farmer

Scotiabank

$23

Hold

-39.09%

Downside

Reiterated

05/14/25

Scotiabank Reaffirms Their Hold Rating on CG Oncology, Inc. (CGON)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CG Oncology, Inc.

1 Month

xxx

Success Rate

4/5 ratings generated profit

Average Return

+12.20%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +12.20% per trade.

3 Months

xxx

Success Rate

4/5 ratings generated profit

Average Return

+26.26%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +26.26% per trade.

1 Year

Sean LaamanMorgan Stanley

Success Rate

5/5 ratings generated profit

Average Return

+64.80%

reiterated a buy rating 2 months ago

Copying Sean Laaman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +64.80% per trade.

2 Years

xxx

Success Rate

5/5 ratings generated profit

Average Return

+64.80%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +64.80% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CGON Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CGON has received 20 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. CGON average Analyst price target in the past 3 months is 71.70.

Each month's total comprises the sum of three months' worth of ratings.

CGON Financial Forecast

CGON Earnings Forecast

Next quarter’s earnings estimate for CGON is -$0.59 with a range of -$0.70 to -$0.44. The previous quarter’s EPS was -$0.57. CGON beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year CGON has Performed in-line its overall industry.

CGON Sales Forecast

Next quarter’s sales forecast for CGON is $514.00K with a range of $0.00 to $5.00M. The previous quarter’s sales results were $1.67M. CGON beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year CGON has Performed in-line its overall industry.

CGON Stock Forecast FAQ

What is CGON’s average 12-month price target, according to analysts?

Based on analyst ratings, CG Oncology, Inc.’s 12-month average price target is 71.70.

What is CGON’s upside potential, based on the analysts’ average price target?

CG Oncology, Inc. has 89.88% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CGON a Buy, Sell or Hold?

CG Oncology, Inc. has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.

What is CG Oncology, Inc.’s price target?

The average price target for CG Oncology, Inc. is 71.70. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $90.00 ,the lowest forecast is $55.00. The average price target represents 89.88% Increase from the current price of $37.76.

What do analysts say about CG Oncology, Inc.?

CG Oncology, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of CGON?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

CG Oncology, Inc. (CGON) Stock Forecast & Price Target

CGON Analyst Ratings

CGON Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering CG Oncology, Inc.

CGON Analyst Recommendation Trends

CGON Financial Forecast

CGON Earnings Forecast

CGON Sales Forecast

CGON Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts